Format

Send to

Choose Destination
Contraception. 2006 Dec;74(6):487-91. Epub 2006 Oct 3.

Androgenicity of the progestin in oral contraceptives does not affect maximal leg strength.

Author information

1
School of Sport and Health Sciences, The University of Exeter, Heavitree Road, Exeter, Devon EX1 2LU, UK. c.e.peters@ex.ac.uk

Abstract

PURPOSE:

This study was conducted to examine androgenicity of the progestin in oral contraceptive pills and its effect on maximal leg strength in females.

METHODS:

Twelve participants who were using a monophasic pill containing 30 microg ethinylestradiol plus either 150 microg levonorgestrel (LEV) or 250 microg norgestimate (NOR) for at least the last 6 months were recruited (mean+/-SEM; LEV: age, 19.8+/-0.3 years; stature, 1.67+/-0.17 m; mass, 65.9+/-1.9 kg; NOR: age, 20.6+/-0.2 years; stature, 1.65+/-0.17 m; mass, 64.6+/-2.4 kg). Three maximal isokinetic extension and flexion tests were performed on three occasions (Days 3-6, 11-14 and 18-21 of the pill cycle) to assess peak extension and peak flexion torque (in Newton meters).

RESULTS:

No significant (p>.05) differences were found in the LEV and NOR groups in peak extension torque (F=0.719; p=.416) or peak flexion torque (F=0.291, p=.601) throughout the pill cycle and between groups.

CONCLUSION:

In this small study, the androgenicity of the progestin in the contraceptive pill had no significant association with maximal strength in these female athletes.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center